Takeda

Takeda Joins Forces with Accenture, AWS to Transform to Cloud-Based Company
Takeda Joins Forces with Accenture, AWS to Transform to Cloud-Based Company
BioSpace
Takeda
Accenture
Amazon Web Services
cloud platforms
Flag link:
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
BioPharma Dive
clinical trials
plasma
COVID-19
Takeda
CSL
Flag link:
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Endpoints
Takeda
RNAi
Arrowhead Pharmaceuticals
Rare Diseases
Flag link:
Fourth-quarter events to watch for big pharma
Fourth-quarter events to watch for big pharma
EP Vantage
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Flag link:
Takeda opens cell therapy manufacturing facility — tucked right in its Boston R&D hub
Takeda opens cell therapy manufacturing facility — tucked right in its Boston R&D hub
Endpoints
Takeda
Boston
cell therapy
drug manufacturing
Flag link:
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
Takeda to sell another non-core portfolio for $260 million to Cheplapharm
Pharmafile
Takeda
Cheplapharm
M&A
Flag link:
Moderna in Talks to Sell 40 Million Coronavirus Vaccine Doses to Japan
Moderna in Talks to Sell 40 Million Coronavirus Vaccine Doses to Japan
Motley Fool
Moderna Therapeutics
Japan
Takeda
vaccines
COVID-19
Flag link:
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?
Endpoints
Ovid Therapeutics
clinical trials
Takeda
Dravet syndrome
Lennox-Gastaut Syndrome
GW Pharma
Flag link:
Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH
Takeda inks up to $500M collaboration with extra-cellular matrix biotech for NASH
Endpoints
Takeda
NASH
Engitix
drug development
Flag link:
Takeda to sell Japan consumer health unit to Blackstone for $2B-plus: reports
Takeda to sell Japan consumer health unit to Blackstone for $2B-plus: reports
Fierce Pharma
Takeda
Blackstone Group
M&A
consumer health
Flag link:
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Fierce Pharma
Takeda
Japan
early retirement
Shire
M&A
Flag link:
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan
Motley Fool
Novavax
Japan
vaccines
Takeda
COVID-19
NVX-CoV2373
Flag link:
Takeda hustles to prevent cancer drug shortage after FDA warning letter
Takeda hustles to prevent cancer drug shortage after FDA warning letter
Fierce Pharma
Takeda
FDA
leuprorelin
Hikari
Flag link:
Platform study designed to rapidly screen potential Covid-19 drugs enrolls first patients
Platform study designed to rapidly screen potential Covid-19 drugs enrolls first patients
MedCity News
COVID-19
Amgen
AbbVie
Takeda
patients
clinical trials
Flag link:
Teva, Takeda offload generics, manufacturing plant to Nichi-Iko in Japanese venture reshuffle
Teva, Takeda offload generics, manufacturing plant to Nichi-Iko in Japanese venture reshuffle
Fierce Pharma
Teva Pharmaceutical
Takeda
Japan
generics
drug manufacturing
Flag link:
A turn-up for Spectrum’s book
A turn-up for Spectrum’s book
EP Vantage
poziotinib
Spectrum Pharmaceuticals
lung cancer
Takeda
Flag link:
Takeda Taps Twist Bioscience to Boost Biologics Discovery Capabilities
Takeda Taps Twist Bioscience to Boost Biologics Discovery Capabilities
BioSpace
Twist Bioscience
Takeda
antibodies
biologics
drug discovery
Flag link:
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale
Endpoints
Takeda
Shire
M&A
OTC
Flag link:
Takeda and Carmine Enter $900 Million Non-Viral Gene Therapy Collaboration
Takeda and Carmine Enter $900 Million Non-Viral Gene Therapy Collaboration
BioSpace
Carmine Therapeutics
Takeda
gene therapy
Flag link:
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra
Endpoints
Takeda
Novartis
Xiidra
Europe
EMA
dry eye disease
Flag link:

Pages